Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of canagliflozin in preparation of drugs for adjuvant treatment of idiopathic pulmonary fibrosis

A technology for pulmonary fibrosis and adjuvant therapy, applied in drug combinations, pharmaceutical formulas, organic active ingredients, etc., can solve the problems of complex mechanism of fibrosis, many adverse reactions, and no significant improvement in the 5-year survival period of patients

Inactive Publication Date: 2018-05-11
JIANGSU WANBANG BIOPHARMLS +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Now the main treatment drugs for IPF are glucocorticoids and immunosuppressants such as dexamethasone, prednisone, tacrolimus, cyclosporine, etc., antioxidant drugs such as N-acetylcysteine, anti-fibrosis drugs such as There are colchicine, D-penicillamine, pyridone, and molecular targeted drugs such as nintedanib, etc. However, due to the complex mechanism of fibrosis and many participating factors, the current common clinical drug treatment methods not only have adverse reactions More, and can only slow down the progression of the disease, no significant improvement in the 5-year survival of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of canagliflozin in preparation of drugs for adjuvant treatment of idiopathic pulmonary fibrosis
  • Application of canagliflozin in preparation of drugs for adjuvant treatment of idiopathic pulmonary fibrosis
  • Application of canagliflozin in preparation of drugs for adjuvant treatment of idiopathic pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1. Method

[0027] 1.1 Experimental objects and grouping

[0028] 40 patients with idiopathic pulmonary fibrosis were enrolled (diagnostic criteria refer to "Guidelines for the Treatment of Idiopathic Pulmonary Fibrosis 2011 Edition"), including 31 males and 9 females. Age ranged from 40 to 76 years, with an average age of (58.3±7.4) were randomly divided into two groups, and group A was set as the canagliflozin treatment group, with 16 males and 4 females, aged 40-67 years, with an average age of (57.0±3.5) years. The course of disease ranged from 10 months to 7 years. years, with an average of (4.8±0.7) years. Group B was set as the conventional treatment group, with 15 males and 5 females, aged 51-76 years, with an average age of (64.6±5.1) years. The course of disease ranged from 1.1 to 10 years. Average (5.2±1.1) years. There was no statistically significant difference in the gender composition of the two groups of patients ( p >0.05), there was no statistically ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of canagliflozin in preparation of drugs for adjuvant treatment of idiopathic pulmonary fibrosis. Clinical trials show that the canagliflozin given as adjuvant therapy for patients with the idiopathic pulmonary fibrosis can significantly treat the idiopathic pulmonary fibrosis, improves breathing difficulties, cough, sputum and other symptoms, and definitely improves the patient's quality of life.

Description

technical field [0001] The invention relates to the application of canagliflozin in the preparation of medicaments for adjuvant treatment of idiopathic pulmonary fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a chronic inflammatory interstitial lung disease characterized by common interstitial pneumonia. And the etiology is unknown. The main manifestation is that the appearance of fibroblast foci leads to the deposition of a large amount of extracellular matrix, the accumulation of collagen, the destruction of alveolar structure, and finally the destruction of normal lung tissue structure. It is a chronic, progressive, irreversible and most common fatal disease. lung disease. The clinical manifestations are progressive dyspnea accompanied by irritating dry cough, and the pulmonary function is restrictive ventilatory disorder. The condition generally continues to deteriorate and eventually dies...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/381A61P11/00
CPCA61K31/381
Inventor 王伟李惠珠乔德水
Owner JIANGSU WANBANG BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com